rivaroxaban reddy 10mg potahovaná tableta
reddy holding gmbh, augsburg array - 17116 rivaroxaban - potahovaná tableta - 10mg - rivaroxaban
rivaroxaban reddy 15mg potahovaná tableta
reddy holding gmbh, augsburg array - 17116 rivaroxaban - potahovaná tableta - 15mg - rivaroxaban
rivaroxaban reddy 20mg potahovaná tableta
reddy holding gmbh, augsburg array - 17116 rivaroxaban - potahovaná tableta - 20mg - rivaroxaban
rivaroxaban reddy 2,5mg potahovaná tableta
reddy holding gmbh, augsburg array - 17116 rivaroxaban - potahovaná tableta - 2,5mg - rivaroxaban
xerdoxo 15mg potahovaná tableta
krka, d.d., novo mesto, novo mesto array - 17116 rivaroxaban - potahovaná tableta - 15mg - rivaroxaban
xerdoxo 20mg potahovaná tableta
krka, d.d., novo mesto, novo mesto array - 17116 rivaroxaban - potahovaná tableta - 20mg - rivaroxaban
xerdoxo 10mg potahovaná tableta
krka, d.d., novo mesto, novo mesto array - 17116 rivaroxaban - potahovaná tableta - 10mg - rivaroxaban
xerdoxo 2,5mg potahovaná tableta
krka, d.d., novo mesto, novo mesto array - 17116 rivaroxaban - potahovaná tableta - 2,5mg - rivaroxaban
xarelto
bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - antitrombotické činidla - přípravek xarelto, podávaný současně s kyselinou acetylsalicylovou (asa) samotnou nebo s asa plus klopidogrel nebo tiklopidin, je indikován k prevenci aterotrombotických příhod u dospělých pacientů po akutním koronárním syndromu (acs) se zvýšenou srdeční biomarkery. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. prevence žilní tromboembolie (vte) u dospělých pacientů, kteří podstoupili elektivní operaci náhrady kyčelního nebo kolenního kloubu. léčba hluboké žilní trombózy (dvt) a plicní embolie (pe) a prevence rekurentní dvt a pe u dospělých. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
rivaroxaban stada 15mg tvrdá tobolka
stada arzneimittel ag, bad vilbel array - 17116 rivaroxaban - tvrdá tobolka - 15mg - rivaroxaban